What is the “delgocitinib preparation” patent about?
Delgocitinib is a drug candidate that targets an intracellular signaling pathway. A patent on “preparation” for delgocitinib typically covers how to manufacture it or make pharmaceutical-ready forms (for example, specific synthetic routes, intermediates, purification conditions, formulation steps, or solid/liquid dosage preparation). The exact scope depends on the particular patent document you mean (there can be multiple related filings across jurisdictions and time).
To identify the right patent, you usually need at least one of these details: a patent number, application number, assignee/company name, or a link to the publication.
How do I find the right delgocitinib preparation patent quickly?
Most searchers use one of these paths:
- By patent number or application number (fastest if you already have it).
- By inventor/assignee name (the company that filed it).
- By keyword search in patent databases using terms like:
- “delgocitinib”
- “preparation”
- “process for preparation”
- “manufacturing”
- “intermediate”
- “formulation”
- “pharmaceutical composition”
If you share the company name or any identifier (even partial), I can help narrow down which “preparation” document matches your intent.
Are there multiple patents covering delgocitinib beyond “preparation”?
Yes. Drug portfolios often split into different patent families, such as:
- compound/invention coverage (the active molecule),
- formulation/drug-product coverage (how it’s delivered),
- manufacturing/process coverage (how it’s made),
- method-of-use coverage (how it’s used to treat disease).
So “preparation” patents are usually only one layer, not the full protection picture.
When does a delgocitinib preparation patent expire?
Patent expiry depends on:
- the filing date (typical base term is about 20 years from the earliest priority date in many jurisdictions),
- whether it’s a granted patent vs. an application,
- patent term adjustments/supplementary protection extensions (where available, jurisdiction-specific),
- and whether there are continuation/divisional filings with different priority dates.
If you provide the specific patent/publication number, the expiry calculation can be made much more precisely.
Can generic or biosimilar versions enter before the preparation patent expires?
It depends on what the limiting patents are. Even if a preparation/process patent expires, other patents in the same portfolio (for example, compound or formulation or method-of-use) can still block entry in some markets. Also, process patents can sometimes be avoided by using an alternative manufacturing route, but that does not remove barriers created by compound/formulation claims.
What details matter most inside a “preparation” patent?
When people look for “preparation” patents, they often want:
- whether it’s a step-by-step synthesis/process claim or a broader “process parameters” claim,
- what starting materials and intermediates are used,
- purification/crystallization conditions,
- yield/purity targets,
- and whether it claims a specific polymorph or solid-state form (if it’s also formulation-related).
These details determine practical relevance for competitors and for scale-up manufacturing.
What I need from you to answer precisely
“Delgocitinib preparation patent” is too broad to point to a single document. Reply with any one of the following, and I’ll identify the relevant patent(s) and summarize the preparation scope:
- a patent number (e.g., EP/US/CN…), or
- a publication number (WO…, EP…, US…), or
- the assignee/company name, or
- a link to the patent page you’re looking at.
Sources
No sources were provided in your message, so I can’t cite any specific patent documents yet.